Myb/SANT DNA binding domain containing 3Genealiases: C9orf30 · L8
Q-omics provides the consensus-scored MSANTD3 profile across patient tissues and cancer cell-line models. MSANTD3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MSANTD3 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, MSANTD3 protein abundance shows 28,603 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where MSANTD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MSANTD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MSANTD3 survival associations across molecular data types. MSANTD3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MSANTD3 RNA expression–survival associations across cancer types. High MSANTD3 expression shows unfavorable associations in HNSC, ACC, MESO, LIHC, BLCA and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MSANTD3 RNA expression.
This table summarizes MSANTD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MSANTD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MSANTD3 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, KIRP, LIHC and COAD. The HNSC box plot shows higher MSANTD3 RNA expression in tumor versus normal tissue (log2 FC = +1.631, t-test p < 0.001).
This table shows molecular features associated with MSANTD3 in patient tissues and cancer cell lines. In patient samples, MSANTD3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MSANTD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
